New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.

Non-profit blasts FDA over flu vaccine approval

The vaccine was recently approved for accelerated licensure by the FDA Vaccines and Related Biological Products Advisory Committee.

The non-profit National Vaccine Information Center is blasting the FDA over the fast-tracking of a squalene-adjuvanted influenza vaccine for use in seniors over age 65.

The Novartis MF59 adjuvanted Fluad vaccine was approved for accelerated licensure by the FDA Vaccines and Related Biological Products Advisory Committee on Sept. 15.

According to a press release from the group, it was approved by, "using limited immunogenicity and safety evidence from a small clinical trial in which only about 1,000 healthy Americans over age 65 were given the adjuvanted vaccine."

“Novartis failed to demonstrate that squalene adjuvanted Fluad was more effective or safer than an unadjuvanted influenza vaccine in the small clinical trial being used to justify accelerated licensure," said NVIC Co-founder and President Barbara Loe Fisher. " In fact, Fluad was shown to be far more reactive and, in some studies, the vaccine was associated with even more serious reactions in the elderly when given a second time."

Discover the right packaging solutions for life sciences in Philadelphia
Explore innovative packaging and supply chain solutions for the life sciences at the largest PACK EXPO East in history, March 18–20. Get ideas from 400+ top exhibitors and connect with colleagues and industry experts—all in one convenient location!
Read More
Discover the right packaging solutions for life sciences in Philadelphia
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts